Targeting B-cell malignancies through human B-cell receptor specific CD4⁺ T cells

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The B-cell receptor (BCR) is a tumor-specific antigen (idiotype) in B-cell malignancies.
• T-cell epitopes within human BCRs that elicit protective immunity require further characterization.

Purpose of the Study:

• To identify and characterize T-cell epitopes derived from BCRs that can stimulate anti-tumor immunity.
• To assess the potential of these epitopes for developing broadly applicable immunotherapies.

Main Methods:

• Identification of 17 BCR peptide-specific CD4+ T-cell epitopes from BCR variable region sequences.
• Analysis of T-cell responses (IFNγ secretion, cytotoxicity) from normal donors and patients.
• Evaluation of epitope binding to multiple HLA DRB1 alleles and recognition of primary tumors.

Main Results:

• 17 BCR-derived CD4+ T-cell epitopes were identified.
• These epitopes stimulated Th1 CD4+ T cells to recognize and lyse autologous tumor cells.
• 10 epitopes were shared among multiple patient tumors, and 16 bound to multiple HLA DRB1 alleles.

Conclusions:

• Identified 17 BCR-derived CD4+ T-cell epitopes with broad HLA DRB1 binding.
• These shared epitopes are present in up to 36% of patients, suggesting a universal immunotherapy approach.
• This finding bypasses the need for individually tailored therapeutic agents targeting BCR idiotype.